Insights

View our latest blog posts, webinars and news stories below

New White Paper: The Impact of the 340B Program on Drug Prices Charged by Manufacturers and Covered Entities

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to … Continue reading

Leavitt Center for Alliances, an HMA Initiative, Drives Collaboration and Solutions

Today, Health Management Associates (HMA) launched the Leavitt Center for Alliances, an HMA Initiative, which aims to elevate the national discourse on healthcare and help healthcare organizations solve their most complex challenges through consensus-based alliances. The Leavitt Center for Alliances (Leavitt Center) is home to expert conveners who have decades of experience in the private … Continue reading

The CARIN Alliance Announces Code of Conduct Accreditation Program with EHNAC

Consumer health app developers are finding ways to help consumers and their physicians make better use of their health data. These apps can now get accredited for their compliance with best practices in managing personal health information, an important step towards building trust that consumers’ health data will be protected as it is moved more … Continue reading

New Leavitt Partners White Paper: The Impact of Medication Noncompliance in Pain Management & What Clinicians Can Do About It

Nonadherence to a prescribed medication regimen for patients with chronic pain is associated with overall lower health outcomes, including increased hospital admissions, costs, and morbidity (quantitative review). Deviations in timing, dosage, frequency, or duration of medication—all components of noncompliance—can cause medical reactions, increased pain, and medication use disorders, and can ultimately lead to emergency care … Continue reading

Digital Health Private Investment Q2 2022

In April 2022, we published a blog post exploring Q1 digital health funding within the US using a framework introduced by Leavitt Partners in a recently published whitepaper. Applying the same methods, we tracked funding across the digital health landscape In Q2. Q2 saw 144 deals in digital health for a total investment of $4.6 billion and an average deal … Continue reading

New Partnership Launches to Advance Access to Care and Treatment, Improve Outcomes for Individuals with Sickle Cell Disease

Partnership Calls on Policymakers to Implement Proposals in 2020 Landmark Report Washington, D.C. — In recognition of World Sickle Cell Day on June 19th, today more than a dozen organizations representing a diverse cross-section of patient advocates, health professional organizations, health insurers and biopharmaceutical companies announced the launch of the Sickle Cell Disease Partnership. The … Continue reading

New white paper highlights seven ways stakeholders can help alleviate medical debt without unintended consequences

As efforts continued at the beginning of 2022 to implement the No Surprises Act aimed at preventing surprise medical bills that patients are often unable to pay, the Kaiser Family Foundation published a report that estimates nearly one in 10 adults have medical debt, and that Americans’ total medical debt could be as high as $195 billion. … Continue reading

Tracking Q1 Digital Health Private Investing In 2022 Using A New Taxonomy

The COVID-19 pandemic significantly accelerated the demand for digital healthcare alternatives. As a result, private investors are looking for promising digital health startups or companies to financially back. One common problem investors will undoubtedly encounter when assessing opportunities in digital health is that stakeholders are often not speaking the same language. In February 2022, Leavitt Partners … Continue reading

New Health Affairs Forefront Article: Imminent VFC Decisions are Critical for RSV Therapy Access

As respiratory syncytial virus (RSV), a seasonal pathogen in young children is challenging the national health care system as part of an unprecedented “tripledemic” with COVID-19 and flu this winter, authors with Leavitt Partners parent company Health Management Associates weigh in on potential coverage pathways for new monoclonal antibody (mAb) preventive therapies for RSV and … Continue reading

Leavitt Partners Future Frame Series: Political Checkpoint

While healthcare leaders seek to broaden and deepen their analysis of the implications of recent federal health policy changes, it is challenging to accurately determine where the industry might be headed in 2022 and beyond. On Tuesday, November 9, 2021, Leavitt Partners’ Senior Director of Health Policy Outreach, Jen Colamonico, moderated a Linkedin Live Political Checkpoint broadcast featuring Liz Wroe, … Continue reading

©2025 Leavitt Partners. All rights reserved.

leavittpartners.com

Privacy Policy